Compare Lowe`s Companies Inc (LOW) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs ResMed Inc. — how do they compare? Lowe`s Companies Inc trades at $204.25 (market cap $114.78B), while ResMed Inc. trades at $195.49 (market cap $28.81B). The key difference: Lowe`s Companies Inc is far larger — about 4× ResMed Inc.'s market cap, and Lowe`s Companies Inc pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| LOW | RMD | |
|---|---|---|
Market Cap | $114.78B | $28.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $293.73 |
52-Week Low | $204.76 | $182.82 |
Enterprise Value | $156.54B | $27.99B |
Dividend Yield | 2.44% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $204.08, down 2.23% on the day, amid a bearish technical signal. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $3.03 exceeding the $2.97 estimate. Revenue for 2025 was $83.67 billion, with a net income margin of 7.51%. The company maintains a strong dividend history, recently declaring a $1.25 per share dividend payable in August 2026.
The outlook is mixed. Strong analyst consensus, with a $260.88 price target and 60.79% buy ratings, suggests upside potential. However, high debt levels, with a debt-to-asset ratio of 82.33% for 2025, and a projected net cash flow deficit of $2.3 billion for 2026 present significant financial risks. Competitive pressures in the home improvement sector remain a key challenge.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
